Project Description

Lipomedix

At a glance

Established in 2011 by Prof. Alberto Gabizon, Lipomedix is an early stage company developing a novel product, Promitil-Pegylated Liposomal Mitomycin C Prodrug (PL-MLP) – an innovative agent for targeted cancer therapy. Promitil® overcomes the tolerability issues associated with MMC toxicity, turning it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those derived from the gastrointestinal tract (stomach, pancreas, colorectal).

Market Potential

Promitil has the potential to generate safe and potent anti-tumor effects in a variety of cancers, including multi-drug resistant tumors. During preclinical development, Promitil® demonstrated a superior antitumor effect relative to many standard forms of chemotherapy (Cisplatin, Irinotecan, Gemcitabine, Doxorubicin) in tumor models and improved tolerability compared to MMC.

Company Highlights

Completion of the ongoing Phase Ib study is expected in Q4 2017. Good safety data and encouraging clinical measures were reported in metastatic colorectal cancer patients.
Prof. Alberto Gabizon, founder, CEO and Chief Scientist of LipoMedix is Prof. of Oncology who was the co-inventor of Doxil® (Shaare Zedek Medical Center, The Hebrew University of Jerusalem) and a renowned scientist and clinician in the field of nanomedicine and cancer therapy.

Key Shareholders

Integra Holdings, Rami Kremien, Kepler Holdings, Prof. Gabizon.

Funding

Business development activity is ongoing to secure future clinical development.

www.lipomedix.com

More Companies